FTRE vs MEDP
FTRE: Fortrea is a global contract research organization that accelerates the delivery of life-changing treatments by providing flexible, science-driven clinical development solutions to pharmaceutical and medical device partners. MEDP: Medpace is a specialized, full-service clinical contract research organization that helps biopharmaceutical and medical device companies accelerate the development of new therapies through every phase of clinical trials.
Side-by-side fundamentals
| Metric | FTRE | MEDP | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $18.49 | $528.12 | |
| Market cap as of 2026-07-23 | $1.7B | $15.0B | |
| P/E as of 2026-07-23 | n/a | 32.69 | |
| PEG as of 2026-07-23 | 0.50 | 2.71 | FTRE lower |
| Net margin as of 2026-07-23 | -16.5% | +17.2% | MEDP higher |
| Gross margin as of 2026-07-23 | +18.9% | +29.1% | MEDP higher |
| Operating margin as of 2026-07-23 | -13.1% | +21.0% | MEDP higher |
| ROE as of 2026-07-23 | -79.1% | +120.9% | MEDP higher |
| ROA as of 2026-07-23 | -16.3% | +24.8% | MEDP higher |
| Debt / equity as of 2026-07-23 | 2.00 | 0.00 | MEDP lower |
| Revenue growth (YoY) as of 2026-07-23 | +0.9% | +24.2% | MEDP higher |
| Revenue CAGR (3y) SEC XBRL | -1.4% | +20.1% | MEDP higher |
| Beta as of 2026-07-23 | 2.02 | 1.15 | |
| 1-year return as of 2026-07-22 close | +218.8% | +10.5% | FTRE higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.